



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/205812/2022

## European Medicines Agency decision P/0153/2022

of 13 May 2022

on the granting of a product specific waiver for human IgG4-based bispecific antibody binding to both B-cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3) (REGN5458) (EMA-003175-PIP01-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

**Only the English text is authentic.**



# European Medicines Agency decision

P/0153/2022

of 13 May 2022

on the granting of a product specific waiver for human IgG4-based bispecific antibody binding to both B-cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3) (REGN5458) (EMA-003175-PIP01-21) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Regeneron Ireland DAC on 20 December 2021 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 25 March 2022 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

Has adopted this decision:

## **Article 1**

A waiver for human IgG4-based bispecific antibody binding to both B-cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3) (REGN5458), all pharmaceutical forms, all routes of administration, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

## **Article 2**

This decision is addressed to Regeneron Ireland DAC, One Warrington Place, D02 HH27 – Dublin, Ireland.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1, as amended.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1, as amended.



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/PDCO/29869/2022  
Amsterdam, 25 March 2022

## Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-003175-PIP01-21

### Scope of the application

#### Active substance(s):

Human IgG4-based bispecific antibody binding to both B-cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3) (REGN5458)

#### Condition(s):

Treatment of multiple myeloma

#### Pharmaceutical form(s):

All pharmaceutical forms

#### Route(s) of administration:

All routes of administration

#### Name/corporate name of the PIP applicant:

Regeneron Ireland DAC

### Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Regeneron Ireland DAC submitted to the European Medicines Agency on 20 December 2021 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 31 January 2022.



## Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended occurs only in adult populations.

The Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

## **Annex I**

### **Grounds for the granting of the waiver**

# 1. Waiver

## **1.1. Condition:**

Treatment of Multiple Myeloma

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- all pharmaceutical forms, all routes of administration;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).